Literature DB >> 16849908

Hypertension complicating cancer chemotherapy.

Joel Handler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16849908      PMCID： PMC8109351          DOI： 10.1111/j.1524-6175.2006.05147.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  18 in total

1.  New antiangiogenic agents for renal cell carcinoma: interferon alfa and thalidomide.

Authors:  Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.

Authors:  Daniel J George; William G Kaelin
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

Review 3.  Inhibition of angiogenesis in cancer patients.

Authors:  Henk M W Verheul; Herbert M Pinedo
Journal:  Expert Opin Emerg Drugs       Date:  2005-05       Impact factor: 4.191

4.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Authors:  Herbert I Hurwitz; Louis Fehrenbacher; John D Hainsworth; William Heim; Jordan Berlin; Eric Holmgren; Julie Hambleton; William F Novotny; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

5.  Kinase inhibition with BAY 43-9006 in renal cell carcinoma.

Authors:  Tanya Ahmad; Tim Eisen
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

6.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.

Authors:  Stacey D Zondor; Patrick J Medina
Journal:  Ann Pharmacother       Date:  2004-06-08       Impact factor: 3.154

Review 9.  Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.

Authors:  Alan B Sandler; David H Johnson; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

10.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  1 in total

Review 1.  Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist.

Authors:  Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher
Journal:  CA Cancer J Clin       Date:  2016-01-19       Impact factor: 508.702
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.